0000950170-24-077402.txt : 20240625 0000950170-24-077402.hdr.sgml : 20240625 20240625170315 ACCESSION NUMBER: 0000950170-24-077402 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240624 FILED AS OF DATE: 20240625 DATE AS OF CHANGE: 20240625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pizzuti Dana CENTRAL INDEX KEY: 0001948238 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 241069769 MAIL ADDRESS: STREET 1: C/O CRINETICS PHARMACEUTICALS, INC. STREET 2: 10222 BARNES CANYON ROAD, BUILDING 2 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-06-24 false 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001948238 Pizzuti Dana C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO CA 92121 false true false false Chief Med and Dev Officer false Common Stock 2024-06-24 4 M false 9500 16.89 A 37286 D Common Stock 2024-06-24 4 S false 9500 45.73 D 27786 D Stock option (Right to Buy) 19.73 2024-06-24 4 M false 9500 0 D 2032-10-10 Common Stock 9500 167792 D The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $45.73 per share. The range of sales prices on the transaction date was $45.53 to $45.88 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Marc Wilson, as attorney-in-fact 2024-06-25